Reckitt Benckiser Group (RB) Given a GBX 6,300 Price Target at UBS Group

UBS Group set a GBX 6,300 ($82.32) price target on Reckitt Benckiser Group (LON:RB) in a research report sent to investors on Thursday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the stock.

A number of other analysts have also recently commented on RB. JPMorgan Chase & Co. set a GBX 7,000 ($91.47) price target on Reckitt Benckiser Group and gave the company a buy rating in a research note on Monday, July 23rd. Cfra set a GBX 7,500 ($98.00) price target on Reckitt Benckiser Group and gave the company a buy rating in a research note on Monday, July 30th. Jefferies Financial Group set a GBX 6,800 ($88.85) price target on Reckitt Benckiser Group and gave the company a neutral rating in a research note on Wednesday, August 1st. Kepler Capital Markets set a GBX 6,300 ($82.32) price target on Reckitt Benckiser Group and gave the company a neutral rating in a research note on Friday, July 27th. Finally, Shore Capital reaffirmed a hold rating on shares of Reckitt Benckiser Group in a research note on Friday, July 27th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have given a buy rating to the company’s stock. Reckitt Benckiser Group has a consensus rating of Hold and an average price target of GBX 6,999.47 ($91.46).

Reckitt Benckiser Group stock traded down GBX 65 ($0.85) during trading hours on Thursday, reaching GBX 6,326 ($82.66). 1,059,684 shares of the company’s stock traded hands, compared to its average volume of 1,720,000. Reckitt Benckiser Group has a fifty-two week low of GBX 5,562 ($72.68) and a fifty-two week high of GBX 8,110.43 ($105.98).

Reckitt Benckiser Group Company Profile

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Read More: What are the benefits of a balanced fund?

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply